CereVasc has concluded patient enrolment in its STRIDE pivotal study, assessing the safety and effectiveness of the ...
BOSTON, Feb. 25, 2025 /PRNewswire/ -- CereVasc, Inc., a clinical-stage medical device company developing novel treatments for neurological diseases, announced today that the first patient has been ...
CereVasc, Inc., a clinical-stage medical device company developing novel, minimally invasive treatments for neurological diseases, announced it has completed patient enrollment in its STRIDE pivotal ...
BOSTON, June 4, 2026 /PRNewswire/ -- CereVasc, Inc., a clinical-stage medical device company developing novel, minimally invasive treatments for neurological diseases, today announced it has ...
BOSTON, July 30, 2025 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, today announced that the 100th patient has ...
BOSTON--(BUSINESS WIRE)--CereVasc, Inc., a company focused on improving the treatment of patients with hydrocephalus, announced today the addition of DJ Cass as Senior Vice President of Business ...
Cerevasc Inc. has formed a partnership with Lianmedical Co. Ltd. to introduce Cerevasc’s medical devices for neurological diseases in the Asian market. Shanghai-based Lianmedical will help market ...
Cerevasc Inc. has treated its first U.S. patient using an investigational device intended for patients suffering from hydrocephalus, one of the most common neurological conditions worldwide.
CereVasc, Inc. announced it has completed patient enrollment in the STRIDE pivotal trial, which is evaluating the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results